A phase II trial of CI-958 in patients with hormone-refractory prostate cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1999-10

AUTHORS

Paul V. Woolley, Fuad S. Freiha, David C. Smith, Lynn Carlson, Janie Hofacker, Nancy Quinn, William Grove, Donald L. Trump

ABSTRACT

PURPOSE: To assess the antitumor activity of the benzothiopyranoindazole CI-958 ¿5-[(2-aminomethyl)amino]-2-[2-(diethylamino)ethyl]-2H- [l]benzothiopyrano[4,3,2-cd]-indazol-8-ol trihydrochloride¿ in hormone-resistant prostate carcinoma, using an intravenous dose of 700 mg/m(2) every 3 weeks. PATIENTS AND METHODS: Patients eligible for this study had advanced prostate carcinoma that had failed hormonal treatment. Changes in an initially elevated prostate-specific antigen (PSA) level and regression of objectively measurable disease were used as response criteria. RESULTS: All 33 patients enrolled were evaluated. Of 30 with elevated PSA levels, 6 had a >50% decline maintained for >30 days; response durations ranged from 105 to 623 days. Eleven patients had objectively measurable disease; two had partial responses (lasting 316 and 461 days) consisting of shrinkage of retroperitoneal nodes and of masses surrounding the rectum and bladder. The survival of all responding patients ranged from 366 days to 709 days and the median survival of all patients was 12 months (range 1-23 + months). Neutropenia was common, but thrombocytopenia was not. Nonhematologic side effects included nausea, vomiting, anorexia, asthenia, and chills, but were usually mild. The drug caused phlebitis when given into peripheral veins and central venous administration is recommended. No consistent reductions in cardiac function were documented by sequential assessment of left ventricular ejection fractions. CONCLUSIONS: CI-958 has modest but definite antitumor activity in hormone-resistant prostate carcinoma. Its toxicities include neutropenia, nausea, vomiting, anorexia, asthenia, chills and phlebitis. More... »

PAGES

511-517

References to SciGraph publications

  • 1985-06. Development of mitoxantrone in INVESTIGATIONAL NEW DRUGS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s002800051126

    DOI

    http://dx.doi.org/10.1007/s002800051126

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1019461349

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/10550573


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged, 80 and over", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Indazoles", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm Staging", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Patient Selection", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Prostate-Specific Antigen", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Prostatic Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tomography, X-Ray Computed", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Failure", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "name": [
                "University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Woolley", 
            "givenName": "Paul V.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Stanford Medicine", 
              "id": "https://www.grid.ac/institutes/grid.240952.8", 
              "name": [
                "Stanford University Medical Center, Palo Alto, CA 94304-2299, USA, US"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Freiha", 
            "givenName": "Fuad S.", 
            "id": "sg:person.0100055227.19", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0100055227.19"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "name": [
                "University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Smith", 
            "givenName": "David C.", 
            "id": "sg:person.015706665604.37", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015706665604.37"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "name": [
                "Laurel Highlands Cancer Program, Conemaugh's Memorial Medical Center and Lee Hospital, Johnstown, PA 15905, USA, US"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Carlson", 
            "givenName": "Lynn", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "name": [
                "University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hofacker", 
            "givenName": "Janie", 
            "id": "sg:person.0762522245.51", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762522245.51"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Stanford Medicine", 
              "id": "https://www.grid.ac/institutes/grid.240952.8", 
              "name": [
                "Stanford University Medical Center, Palo Alto, CA 94304-2299, USA, US"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Quinn", 
            "givenName": "Nancy", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Pfizer (United States)", 
              "id": "https://www.grid.ac/institutes/grid.410513.2", 
              "name": [
                "Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105, USA, US"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Grove", 
            "givenName": "William", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "name": [
                "University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Trump", 
            "givenName": "Donald L.", 
            "id": "sg:person.0710021450.77", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710021450.77"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.1016/0021-9681(61)90060-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043596267"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00174154", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046492696", 
              "https://doi.org/10.1007/bf00174154"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm00384a021", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055945720"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm00403a009", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055946405"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1999-10", 
        "datePublishedReg": "1999-10-01", 
        "description": "PURPOSE: To assess the antitumor activity of the benzothiopyranoindazole CI-958 \u00bf5-[(2-aminomethyl)amino]-2-[2-(diethylamino)ethyl]-2H- [l]benzothiopyrano[4,3,2-cd]-indazol-8-ol trihydrochloride\u00bf in hormone-resistant prostate carcinoma, using an intravenous dose of 700 mg/m(2) every 3 weeks.\nPATIENTS AND METHODS: Patients eligible for this study had advanced prostate carcinoma that had failed hormonal treatment. Changes in an initially elevated prostate-specific antigen (PSA) level and regression of objectively measurable disease were used as response criteria.\nRESULTS: All 33 patients enrolled were evaluated. Of 30 with elevated PSA levels, 6 had a >50% decline maintained for >30 days; response durations ranged from 105 to 623 days. Eleven patients had objectively measurable disease; two had partial responses (lasting 316 and 461 days) consisting of shrinkage of retroperitoneal nodes and of masses surrounding the rectum and bladder. The survival of all responding patients ranged from 366 days to 709 days and the median survival of all patients was 12 months (range 1-23 + months). Neutropenia was common, but thrombocytopenia was not. Nonhematologic side effects included nausea, vomiting, anorexia, asthenia, and chills, but were usually mild. The drug caused phlebitis when given into peripheral veins and central venous administration is recommended. No consistent reductions in cardiac function were documented by sequential assessment of left ventricular ejection fractions.\nCONCLUSIONS: CI-958 has modest but definite antitumor activity in hormone-resistant prostate carcinoma. Its toxicities include neutropenia, nausea, vomiting, anorexia, asthenia, chills and phlebitis.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1007/s002800051126", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": false, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2688757", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1088364", 
            "issn": [
              "0344-5704", 
              "1432-0843"
            ], 
            "name": "Cancer Chemotherapy and Pharmacology", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "6", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "44"
          }
        ], 
        "name": "A phase II trial of CI-958 in patients with hormone-refractory prostate cancer", 
        "pagination": "511-517", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "5cb9deba13e0a024eabd46e23bc3a75d5d6a21663756da88e1b74080c0a19a5f"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "10550573"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "7806519"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s002800051126"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1019461349"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s002800051126", 
          "https://app.dimensions.ai/details/publication/pub.1019461349"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-11T01:07", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8697_00000512.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://link.springer.com/10.1007%2Fs002800051126"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002800051126'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002800051126'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002800051126'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002800051126'


     

    This table displays all metadata directly associated to this object as RDF triples.

    198 TRIPLES      21 PREDICATES      47 URIs      35 LITERALS      23 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s002800051126 schema:about N0c75b155302f4a07b46aedb127fed0a6
    2 N353ee5e22a814eb0a9762aedb1529c89
    3 N365255f67c794da791bbb7edf97fc0f8
    4 N3b55fa69f49748b8853d92a2be08b8bf
    5 N521fd1f9406147e2882d9a4e2c13f545
    6 N640bc7696a0d40808bda5d1c4c5a5334
    7 N899cc1ec06ac4c3a8cbfdd037d65372c
    8 N9411f6f10a0a421991c54c200f8dc72f
    9 N94a2fc2bde8844aaa46a85010b75a0a9
    10 N9680973b8b5d46c582f7f558dbea1f49
    11 Nac6c0d2650174c6e8ada4c69bf9e9643
    12 Nae3c9f7539fd4d6c99546fd8a3e70f9c
    13 Nca1d70994f2f4793985ec235b70284f8
    14 Nd9749dee98c7484ab8ed09d3b4313b19
    15 anzsrc-for:11
    16 anzsrc-for:1103
    17 schema:author N372b6c396ae242409043b12d6828295e
    18 schema:citation sg:pub.10.1007/bf00174154
    19 https://doi.org/10.1016/0021-9681(61)90060-1
    20 https://doi.org/10.1021/jm00384a021
    21 https://doi.org/10.1021/jm00403a009
    22 schema:datePublished 1999-10
    23 schema:datePublishedReg 1999-10-01
    24 schema:description PURPOSE: To assess the antitumor activity of the benzothiopyranoindazole CI-958 ¿5-[(2-aminomethyl)amino]-2-[2-(diethylamino)ethyl]-2H- [l]benzothiopyrano[4,3,2-cd]-indazol-8-ol trihydrochloride¿ in hormone-resistant prostate carcinoma, using an intravenous dose of 700 mg/m(2) every 3 weeks. PATIENTS AND METHODS: Patients eligible for this study had advanced prostate carcinoma that had failed hormonal treatment. Changes in an initially elevated prostate-specific antigen (PSA) level and regression of objectively measurable disease were used as response criteria. RESULTS: All 33 patients enrolled were evaluated. Of 30 with elevated PSA levels, 6 had a >50% decline maintained for >30 days; response durations ranged from 105 to 623 days. Eleven patients had objectively measurable disease; two had partial responses (lasting 316 and 461 days) consisting of shrinkage of retroperitoneal nodes and of masses surrounding the rectum and bladder. The survival of all responding patients ranged from 366 days to 709 days and the median survival of all patients was 12 months (range 1-23 + months). Neutropenia was common, but thrombocytopenia was not. Nonhematologic side effects included nausea, vomiting, anorexia, asthenia, and chills, but were usually mild. The drug caused phlebitis when given into peripheral veins and central venous administration is recommended. No consistent reductions in cardiac function were documented by sequential assessment of left ventricular ejection fractions. CONCLUSIONS: CI-958 has modest but definite antitumor activity in hormone-resistant prostate carcinoma. Its toxicities include neutropenia, nausea, vomiting, anorexia, asthenia, chills and phlebitis.
    25 schema:genre research_article
    26 schema:inLanguage en
    27 schema:isAccessibleForFree false
    28 schema:isPartOf Na3b1f8013c744bbcb7977600b62306fc
    29 Ne9ed092302c44e12a98a80f930718af0
    30 sg:journal.1088364
    31 schema:name A phase II trial of CI-958 in patients with hormone-refractory prostate cancer
    32 schema:pagination 511-517
    33 schema:productId N215061c61a354c3fb0d322a2ceb3a4e9
    34 N4489d528ff064951a7c8c0ba2124dfa5
    35 N811d8b06683045f68580ffdba681b4d7
    36 N89d87d98ba484a608683ba11c673dc74
    37 Na84eff9b1e1f492da5618aa1038ad98e
    38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019461349
    39 https://doi.org/10.1007/s002800051126
    40 schema:sdDatePublished 2019-04-11T01:07
    41 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    42 schema:sdPublisher Nba26c1bde63946a5a80a33e8192059f1
    43 schema:url http://link.springer.com/10.1007%2Fs002800051126
    44 sgo:license sg:explorer/license/
    45 sgo:sdDataset articles
    46 rdf:type schema:ScholarlyArticle
    47 N0c75b155302f4a07b46aedb127fed0a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    48 schema:name Antineoplastic Agents
    49 rdf:type schema:DefinedTerm
    50 N1485e60bcae74096823421c50941834a rdf:first Na74dea9aeccc4563bff6acb3c7eec8d8
    51 rdf:rest N500c76ece62a4f9286762042a3ea0cad
    52 N19e89b4240b7410bb1ed329e2da75622 rdf:first Na9c4b725c8af44e9ad1a6e973385e5df
    53 rdf:rest Na64a5389fffb4eafba37d4820d89a055
    54 N215061c61a354c3fb0d322a2ceb3a4e9 schema:name readcube_id
    55 schema:value 5cb9deba13e0a024eabd46e23bc3a75d5d6a21663756da88e1b74080c0a19a5f
    56 rdf:type schema:PropertyValue
    57 N329fcd2ca7be47768dde38145328e25c schema:affiliation https://www.grid.ac/institutes/grid.240952.8
    58 schema:familyName Quinn
    59 schema:givenName Nancy
    60 rdf:type schema:Person
    61 N32bd1aaccf9f42ba8601545a5aa8a58b schema:name University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US
    62 rdf:type schema:Organization
    63 N353ee5e22a814eb0a9762aedb1529c89 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    64 schema:name Adult
    65 rdf:type schema:DefinedTerm
    66 N365255f67c794da791bbb7edf97fc0f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    67 schema:name Humans
    68 rdf:type schema:DefinedTerm
    69 N372b6c396ae242409043b12d6828295e rdf:first N768ca5df95474f1f85d93d809188d69c
    70 rdf:rest Nb6d967e79faf409cbd8d669261faa2a8
    71 N3b55fa69f49748b8853d92a2be08b8bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    72 schema:name Aged
    73 rdf:type schema:DefinedTerm
    74 N4489d528ff064951a7c8c0ba2124dfa5 schema:name nlm_unique_id
    75 schema:value 7806519
    76 rdf:type schema:PropertyValue
    77 N500c76ece62a4f9286762042a3ea0cad rdf:first sg:person.0762522245.51
    78 rdf:rest Nc3287618a73e4819b914c26bd2787c93
    79 N5198454f0401491e8d59ea06558cc449 rdf:first sg:person.015706665604.37
    80 rdf:rest N1485e60bcae74096823421c50941834a
    81 N521fd1f9406147e2882d9a4e2c13f545 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    82 schema:name Indazoles
    83 rdf:type schema:DefinedTerm
    84 N640bc7696a0d40808bda5d1c4c5a5334 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    85 schema:name Tomography, X-Ray Computed
    86 rdf:type schema:DefinedTerm
    87 N768ca5df95474f1f85d93d809188d69c schema:affiliation N32bd1aaccf9f42ba8601545a5aa8a58b
    88 schema:familyName Woolley
    89 schema:givenName Paul V.
    90 rdf:type schema:Person
    91 N811d8b06683045f68580ffdba681b4d7 schema:name dimensions_id
    92 schema:value pub.1019461349
    93 rdf:type schema:PropertyValue
    94 N87dbff2b432e417eb9a30e51b7ed20e2 schema:name Laurel Highlands Cancer Program, Conemaugh's Memorial Medical Center and Lee Hospital, Johnstown, PA 15905, USA, US
    95 rdf:type schema:Organization
    96 N899cc1ec06ac4c3a8cbfdd037d65372c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    97 schema:name Prostatic Neoplasms
    98 rdf:type schema:DefinedTerm
    99 N89d87d98ba484a608683ba11c673dc74 schema:name doi
    100 schema:value 10.1007/s002800051126
    101 rdf:type schema:PropertyValue
    102 N9411f6f10a0a421991c54c200f8dc72f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    103 schema:name Aged, 80 and over
    104 rdf:type schema:DefinedTerm
    105 N94a2fc2bde8844aaa46a85010b75a0a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    106 schema:name Patient Selection
    107 rdf:type schema:DefinedTerm
    108 N9680973b8b5d46c582f7f558dbea1f49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    109 schema:name Neoplasm Staging
    110 rdf:type schema:DefinedTerm
    111 Na3b1f8013c744bbcb7977600b62306fc schema:issueNumber 6
    112 rdf:type schema:PublicationIssue
    113 Na64a5389fffb4eafba37d4820d89a055 rdf:first sg:person.0710021450.77
    114 rdf:rest rdf:nil
    115 Na74dea9aeccc4563bff6acb3c7eec8d8 schema:affiliation N87dbff2b432e417eb9a30e51b7ed20e2
    116 schema:familyName Carlson
    117 schema:givenName Lynn
    118 rdf:type schema:Person
    119 Na84eff9b1e1f492da5618aa1038ad98e schema:name pubmed_id
    120 schema:value 10550573
    121 rdf:type schema:PropertyValue
    122 Na9c4b725c8af44e9ad1a6e973385e5df schema:affiliation https://www.grid.ac/institutes/grid.410513.2
    123 schema:familyName Grove
    124 schema:givenName William
    125 rdf:type schema:Person
    126 Nac6c0d2650174c6e8ada4c69bf9e9643 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    127 schema:name Treatment Failure
    128 rdf:type schema:DefinedTerm
    129 Nae3c9f7539fd4d6c99546fd8a3e70f9c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    130 schema:name Prostate-Specific Antigen
    131 rdf:type schema:DefinedTerm
    132 Nb6d967e79faf409cbd8d669261faa2a8 rdf:first sg:person.0100055227.19
    133 rdf:rest N5198454f0401491e8d59ea06558cc449
    134 Nba26c1bde63946a5a80a33e8192059f1 schema:name Springer Nature - SN SciGraph project
    135 rdf:type schema:Organization
    136 Nbed22702d7b9467cbad56e13c18dedcf schema:name University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US
    137 rdf:type schema:Organization
    138 Nc3287618a73e4819b914c26bd2787c93 rdf:first N329fcd2ca7be47768dde38145328e25c
    139 rdf:rest N19e89b4240b7410bb1ed329e2da75622
    140 Nca1d70994f2f4793985ec235b70284f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    141 schema:name Male
    142 rdf:type schema:DefinedTerm
    143 Ncb2e5ed5b1de49d9aa798205af868382 schema:name University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US
    144 rdf:type schema:Organization
    145 Nd9749dee98c7484ab8ed09d3b4313b19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    146 schema:name Middle Aged
    147 rdf:type schema:DefinedTerm
    148 Ndc6ae4ea26744706b9785da28ad4508f schema:name University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US
    149 rdf:type schema:Organization
    150 Ne9ed092302c44e12a98a80f930718af0 schema:volumeNumber 44
    151 rdf:type schema:PublicationVolume
    152 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    153 schema:name Medical and Health Sciences
    154 rdf:type schema:DefinedTerm
    155 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    156 schema:name Clinical Sciences
    157 rdf:type schema:DefinedTerm
    158 sg:grant.2688757 http://pending.schema.org/fundedItem sg:pub.10.1007/s002800051126
    159 rdf:type schema:MonetaryGrant
    160 sg:journal.1088364 schema:issn 0344-5704
    161 1432-0843
    162 schema:name Cancer Chemotherapy and Pharmacology
    163 rdf:type schema:Periodical
    164 sg:person.0100055227.19 schema:affiliation https://www.grid.ac/institutes/grid.240952.8
    165 schema:familyName Freiha
    166 schema:givenName Fuad S.
    167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0100055227.19
    168 rdf:type schema:Person
    169 sg:person.015706665604.37 schema:affiliation Ncb2e5ed5b1de49d9aa798205af868382
    170 schema:familyName Smith
    171 schema:givenName David C.
    172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015706665604.37
    173 rdf:type schema:Person
    174 sg:person.0710021450.77 schema:affiliation Ndc6ae4ea26744706b9785da28ad4508f
    175 schema:familyName Trump
    176 schema:givenName Donald L.
    177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710021450.77
    178 rdf:type schema:Person
    179 sg:person.0762522245.51 schema:affiliation Nbed22702d7b9467cbad56e13c18dedcf
    180 schema:familyName Hofacker
    181 schema:givenName Janie
    182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762522245.51
    183 rdf:type schema:Person
    184 sg:pub.10.1007/bf00174154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046492696
    185 https://doi.org/10.1007/bf00174154
    186 rdf:type schema:CreativeWork
    187 https://doi.org/10.1016/0021-9681(61)90060-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043596267
    188 rdf:type schema:CreativeWork
    189 https://doi.org/10.1021/jm00384a021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055945720
    190 rdf:type schema:CreativeWork
    191 https://doi.org/10.1021/jm00403a009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055946405
    192 rdf:type schema:CreativeWork
    193 https://www.grid.ac/institutes/grid.240952.8 schema:alternateName Stanford Medicine
    194 schema:name Stanford University Medical Center, Palo Alto, CA 94304-2299, USA, US
    195 rdf:type schema:Organization
    196 https://www.grid.ac/institutes/grid.410513.2 schema:alternateName Pfizer (United States)
    197 schema:name Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105, USA, US
    198 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...